Patient Rating:

4.7 out of 5

44 Patient Ratings
11 Patient Comments

Terry D. Box, M.D.

Clinical Details

Locations

Schedule An Appointment Clinical Office Address
(801) 581-3761 University Hospital
50 N Medical Dr
Salt Lake City, UT 84132
Map
(801) 581-2634 University Hospital
Liver Transplant
50 N Medical Dr
Salt Lake City, UT 84132
Map

Bio

Terry Box, MD, is an Associate Professor in the Department of Internal Medicine at the University of Utah School of Medicine. He is also a Huntsman Cancer Institute (HCI) investigator and a member of HCI's Gastrointestinal Cancer Program. Dr. Box is certified by the American Board of Internal Medicine and the National Board of Medical Examiners.

Dr. Box's expertise is in diagnosing and treating diseases of the liver. He has specific expertise in hepatitis B and C, hepatocellular carcinoma, and liver transplantation. Dr. Box completed his medical degree at the University of Texas Southwestern Medical School, followed by residency and fellowship at the University of Utah.

Board Certification and Academic Information

Academic Departments Internal Medicine - Associate Professor (Clinical)
Academic Divisions Gastroenterology
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Gastro)
American Board of Internal Medicine (Sub:Transplant Hepatol)
National Board of Medical Examiners

Patient Ratings

The Patient Rating score is an average of all responses to physician related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending doctor
4.5
My confidence in doctor
4.7
Time doctor spent with me
4.7
Doctor spoke using clear language
4.7
Doctor's effort to include me in decisions
4.7
Doctor's concern for questions & worries
4.7
Doctor's explanation of condition/problem
4.7
Wait time at clinic
4.5
Doctor's friendliness and courtesy
4.7

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

February 08, 2014

I am very appreciative of the fact that the Doctors didn't sugar-coat the seriousness of my disease, telling me very bluntly what I could expect, what I had to do before proceeding with the course of treatment and what my prognosis was without treatment.

November 04, 2013

Dr.Box has always treated us like we are his only patients when we come in and that is refreshing!

October 12, 2013

I like working with the pre-liver transplant team. Very knowledgeable doctors can answer any of my questions.

August 06, 2013

Dr. Box was kind and made the whole medical experience nonthreatening.

July 22, 2013

I was very impressed with Dr. Box. He was able to set my mind at ease on some concerns I had and he was very knowledgeable in the area I needed.

July 01, 2013

it was all very good!!!!!!!

June 26, 2013

Absolutely love Dr. Box! He seems genuinely concerned for my husband and responds very quickly to my phone calls and texts.

May 27, 2013

very pleased...for the first time....

December 28, 2012

explained well

March 01, 2012

excellant experience

January 06, 2012

Dr. Box and the nursing staff were great to work with.

Academic Profile

Research Interests

  • Liver Cancer
  • Hepatitis C
  • Liver Transplantation
  • Hepatitis B
  • Liver Diseases
  • Liver Failure

Board Certification and Academic Information

Academic Departments Internal Medicine - Associate Professor (Clinical)
Academic Divisions Gastroenterology
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Gastro)
American Board of Internal Medicine (Sub:Transplant Hepatol)
National Board of Medical Examiners

Academic Bio

Dr. Terry Box is an Associate Professor of Medicine at the University of Utah, where he joined the faculty in 2009 after a very successful career in hepatology and liver transplantation at the LDS Hospital in Salt Lake City from 1983 to 2009.

Dr. Box obtained an undergraduate degree in mathematics from the University of Texas at Austin and obtained his medical degree from the University of Texas Southwestern Medical School in Dallas. He completed his Residency in Internal Medicine in 1981 and Fellowship in Gastroenterology, Hepatology and Nutrition at the University of Utah in 1983.

At the University of Utah, as a member of the Liver Transplant Program, he continues his duties in the clinical care of patients with liver disease both before and after liver transplantation.

Since 1995, he has been actively involved in clinical research in the areas of chronic viral Hepatitis B and C and non-alcoholic fatty liver disease as well as Transplant Hepatology. He has had related abstracts accepted at AASLD and EASL and has had publications in peer reviewed and other publications. Currently, he is principal investigator of 10 active clinical trials and a sub-investigator on others with colleagues in the University Hepatology group. He has been an invited speaker for national and international seminars, congresses and educational events in the disciplines of hepatology and liver transplant and has served on national committees that oversee liver transplant programs in the United States.

As a Transplant Hepatologist, he has a rather unique perspective, having been the recipient of a liver transplant in October 2002.

Education

Education History

Type School Degree
Other Training California Pacific Medical Center
Clinical Transplant Hepatology
Fellowship University of Utah Affiliated Hospitals
Gastroenterology, Clinical Nutrition and Hepatology
Fellow
Chief Resident University of Utah School of Medicine
Internal Medicine
Chief Resident
Residency University of Utah School of Medicine
Internal Medicine
Resident
Internship University of Utah School of Medicine
Intern
Professional Medical University of Texas Southwestern
Medicine
M.D.
Undergraduate University of Texas, Austin
Mathematics
B.A.

Publications

Selected Provider Publications

Journal Article

  1. Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, Hutson WR, Boucher K, Box (2012)Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.  Liver Transplantation, 18(4),423-33
  2. Remien CH, Adler FR, Waddoups L, Box TD, Sussman N(2012)Mathematical modeling of liver injury and dysfunction after acetaminophen overdose: early discrimination between survival and death.  Hepatology, 56(2),727-34
  3. Schwartz J, Thiesset H, Box T, Hutson W, Sorensen J(2012)

    Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.

     Liver Transplantation, 18(11),1395-6
  4. Salek J, Byrne J, Box T, Longo N, Sussman N(2010)Recurrent Liver Failure in a 25-Year-Old Female  Liver Transplantation, 16(9),1049-1053
  5. Sulkowski M, Vierling J, Brown K, Flamm B, Kwo P, Mullen K, Box T, et a(2008)Probability of Sustained Virologic Response is Associated with the magnitude of HCV RNA Reduction at Week 4 of Treatment with Peg-Interferon plus Ribavirin; Results of the IDEAL Trial  Hepatology, 48(4 Suppl),1144A
  6. Ahmed F, Jacobson IM, Brown RS, Vierling J, Box T, Cochran JL, et a(2004)Arrhythmias During Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C: Observations from the WIN-R Trial  Gastroenterology, 126(4 Suppl 2),M1226
  7. Gaglio PJ, Rodriguez-Torres M, Box T, et a(2004)Racial Differences in Response Rates to Consensus Interferon in HCV Infected Patients Naïve to Previous Therapy  Journal of Clinical Gastroenterology, 38(7),599-604
  8. Burgert SJ, Burke JP, Box T(1995)Reversible nitrofurantoin-induced chronic active hepatitis and hepatic cirrhosis in a patient awaiting liver transplantation.  Transplantation, 59(3),448-9
  9. Box TD, Keefe EB, Esquivel C(1993)Liver Transplantation in Elderly Patients  Practical Gastroenterology, 1722-27

Abstract

  1. Pauly MP, Poordad F, Gibas AL, Freilich B, Reindollar RW, Box TD, et al(2011)Effect of Cigarette Smoking on Virologic Response in Patients Treated for Chronic Hepatitis C (CHC) in the IDEAL Study  , 140(5),S-947

Poster

  1. Lawitz E, Box TD, Pruitt RE, Rodriguez-Torres M, Nguyen T, Lalezari J, Vargas H, Goff J, Hinestrosa F, Luketic V, Mehra P, Dubuc Patrick G, Donovan E, Chen J, Pietropaolo K, Zhou XJ, Sullivan-Bólyai Z, and Mayers (2012)

    High Rates of Rapid Virologic Response and Complete Early Virologic Response with IDX184, Pegylated Interferon and Ribavirin in Genotype 1 HCV-Infected Subjects: Interim Results

     ,
  2. Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, Dieterich D, Esteban Mur R, Everson G, Fallon M, Ferenci P, Flisiak R, George J, Ghalib R, Gitlin N, Gladysz A, Gordon S, Greenbloom S, Hassanein T, Jacobson I, Jeffers L, Kowdley K, Lawitz E, Lee S, Leggett B, Lueth S, Nelson D, Pockros P, Rodriguez-Torres M, Rustgi V, Serfaty L, Sherman M, Shiffman M, Sola R, Sulkowski M, Vargas H, Vierling J, Yoffe B, Ishak L, Fontana D, Xu D, Lester J, Gray T, Horga A, Hillson J, Ramos E, Lopez-Talavera JC, Muir A, EMERGE Study Grou(2012)Pegylated Interferon-lambda (Lambda) Shows Superior Viral Response With Improved Safety and Tolerability Versus Pegylated Interferon Alfa-2a (alfa-2a) in Patients with Chronic HCV Infection (G1/2/3/4): EMERGE Phase IIB Through Week 12.  ,
  3. Rodriguez-Torres M, Bacon B, Gordon S, Rubin R, Box T, et al(2011)Unique Pattern Of Virologic Response In Patients With Genotype-1 Hcv: A Phase Ii Study Of Cts-1027 In Combination With Peginteferon /Ribavirin (Soc) In Null Responders  ,
  4. Remien C, Adler FR, Waddoups L, Box T, Sussman N(2010)A Mathematical Model of Acetaminophen Toxicity to Assess Prognosis at the Time of Administration  ,
  5. Terrault N, Cooper C, Balart LA, Larrey DG, Box T, et al(2010)Phase II randomized, partially blind, parallel-group study of oral danoprevir (RG7227) with PegIFN alfa-2a (PEGASYS) plus ribavirin (COPEGUS) in treatment-naive genotype 1 patients with CHC: Results of planned Week 12 interim analysis of the ATLAS study  ,

Clinical Trials

Clinical Trials

Video & News